Archives for October 6, 2014

← 2014

Dutch R&D firm has AMD claim in its sights

By Lynda Searby

The results of a clinical trial confirming the bioavailability of dried lutein-enriched egg yolk bring Dutch biotech firm Newtricious a step closer to submitting a dossier for an article 14 or 13.5 age-related macular degeneration (AMD) claim in Europe.